Efficacy of fluconazole in cryptococcal meningitis

Area of Science:

• Infectious Diseases
• Mycology
• Clinical Pharmacology

Background:

• Cryptococcal meningitis is a serious opportunistic infection in patients with Acquired Immune Deficiency Syndrome (AIDS).
• Traditional treatments like amphotericin B have limitations, necessitating exploration of alternative antifungal agents.

Purpose of the Study:

• To evaluate the efficacy and safety of oral fluconazole for treating cryptococcal meningitis in AIDS patients.
• To assess fluconazole's role as both primary and secondary therapy.
• To determine the effectiveness of fluconazole maintenance therapy in preventing disease recurrence.

Main Methods:

• A clinical trial involving 32 patients with AIDS and cryptococcal meningitis.
• Fluconazole administered as primary therapy (200-400 mg/day) or second-line therapy after amphotericin B.
• Maintenance therapy (100-200 mg/day) evaluated for relapse prevention.

Main Results:

• Primary therapy with fluconazole achieved favorable clinical response in 67% and negative CSF cultures in 86% of evaluable patients.
• Second-line therapy showed positive clinical and mycological responses in over 60% of patients.
• Maintenance therapy demonstrated a low relapse rate of 3.2 cases per 1000 patient-weeks.

Conclusions:

• Oral fluconazole is an efficacious and safe treatment option for cryptococcal meningitis in AIDS patients.
• Fluconazole offers a viable alternative for both initial treatment and salvage therapy.
• Low relapse rates suggest effectiveness in long-term management and prevention of recurrence.